New Lightning Sensors Could Detect Tahoe Wildfires in Seconds. Here’s How They Work
A real-time lightning detection system developed by UF Innovate | Accelerate resident client FNN is helping California officials better prepare for wildfires, offering earlier alerts to reduce disaster risk.
Oragenics Selects Southern Star Research As Clinical Research Organization for ONP-002 Phase IIa Trial
UF Innovate | Accelerate graduate Oragenics, Inc., announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion.
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SGT-501, the Company’s novel, AAV-based investigational gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT).
Taming Wild Fires Before They Spiral: Part 2 – User Experience
UF Innovate | Accelerate resident client Fire Neural Network (FNN) was spotlighted for its AI-powered wildfire detection system, which emphasizes user experience in addressing critical environmental challenges.
SandboxAQ and iOncologi Partner To Accelerate Brain Cancer Treatment With AI-Driven Drug Discovery for Glioblastoma
SandboxAQ and UF startup iOncologi have announced a strategic collaboration to co-develop, validate, and commercialize a novel high-fidelity mRNA vaccine targeting glioblastoma—the most common and aggressive malignant brain tumor in adults.
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement To Support ONP-002 Clinical Development
UF Innovate | Accelerate graduate Oragenics, Inc., has announced a manufacturing agreement with Sterling Pharma Solutions, a leading U.S.-based CDMO with multiple development and production facilities.
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Solid Biosciences, which acquired UF startup AavantiBio, announced FDA and Health Canada approval to begin clinical trials of SGT-501, a gene therapy targeting CPVT, a severe heart rhythm disorder caused by RYR2 mutations.
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, has announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA’s lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
Vertaeon, an Established Risk and Sustainability SaaS Platform Provider, Moves Deeper Into Artificial Intelligence With New Parent Entity AltaScient
UF Innovate | Accelerate client company Vertaeon is expanding its footprint in AI-powered risk analytics under its new parent entity, AltaScient.
Taming Wild Fires Before They Spiral – Part 1: Solutions
UF Innovate | Accelerate resident client Fire Neural Network (FNN) was spotlighted for its AI-driven wildfire detection platform, which aims to prevent devastating blazes by catching them early with low-cost sensors and advanced analytics.